Latest revenue
$592.1M
as of 2026-03-31
Latest net income
$-527.1M
as of 2026-03-31
Net margin
-89.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $8.68B
- Enterprise value
- $8.68B
- P/E (trailing)
- 11.4×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $343.12
- 52-wk low
- $211.43
- Beta
- —
- Shares out
- 30.2M
5-year trend
About BIO
Business description and risk factors will appear here once BIO's latest filing is fully ingested.
Profitability
Gross margin
51.9%
3.5%Operating margin
1.8%
82.6%Net margin
29.4%
140.9%Return on equity
10.2%
148.3%Return on assets
7.2%
136.5%Leverage
Debt / equity
0.42×
488.0%Long-term debt / equity
0.16×
17.4%Debt / assets
29.5%
343.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $592.1M | +1.1% | $-527.1M | -923.6% | -89.0% |
Q4 2025 2025-12-31 | $693.2M | +3.8% | $338.2M | +130.8% | 48.8% |
Q3 2025 2025-09-30 | $653.0M | +0.5% | $39.9M | -93.9% | 6.1% |
Q2 2025 2025-06-30 | $651.6M | +2.1% | $317.8M | +117.8% | 48.8% |
Q1 2025 2025-03-31 | $585.4M | -4.2% | $64.0M | -83.3% | 10.9% |
Q4 2024 2024-12-31 | $667.5M | — | $-1.10B | — | -164.7% |
Q3 2024 2024-09-30 | $649.7M | +2.8% | $653.2M | +514.7% | 100.5% |
Q2 2024 2024-06-30 | $638.5M | -6.3% | $-1.78B | -63.0% | -279.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on BIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$349.9K
Net activity
−$349.9K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-05-11 | Eva Anette Engelhardt EVP, President, CDG | Sale | 550 | $246.54 | $135.6K | |
| 2025-11-06 | James Barry EVP, President, LSG | Sale | 700 | $306.18 | $214.3K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BIO
Institutional value
$3.33B
Total shares held
12.7M
Distinct holders
261
-135 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | First Eagle Investment Management, LLC | 2.6M | $725.5M | +32.3K (+1.3%) | Added |
| 2 | BlackRock, Inc. | 1.7M | $468.3M | -888 (-0.1%) | Trimmed |
| 3 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $303.6M | +12.3K (+1.1%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 831.2K | $231.7M | — | New |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 829.2K | $231.1M | — | New |
| 6 | Capital World Investors | 450.0K | $125.4M | — | New |
| 7 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 426.0K | $118.8M | +31.0K (+7.8%) | Added |
| 8 | Capital Research Global Investors | 385.6K | $107.5M | -108.9K (-22.0%) | Trimmed |
| 9 | UBS Group AG | 354.4K | $98.8M | +138.2K (+63.9%) | Added |
| 10 | SEI INVESTMENTS CO | 287.9K | $80.3M | -4.0K (-1.4%) | Trimmed |
| 11 | PARNASSUS INVESTMENTS, LLC | 254.3K | $70.9M | +2.2K (+0.9%) | Added |
| 12 | Mawer Investment Management Ltd. | 188.8K | $52.6M | -45.2K (-19.3%) | Trimmed |
| 13 | FRANKLIN RESOURCES INC | 170.4K | $47.5M | +33.1K (+24.1%) | Added |
| 14 | Assenagon Asset Management S.A. | 147.8K | $41.2M | +145.6K (+6586.3%) | Added |
| 15 | Bank of New York Mellon Corp | 126.9K | $35.4M | -2.5K (-1.9%) | Trimmed |
| 16 | CIBC Bancorp USA Inc. | 120.1K | $33.5M | — | New |
| 17 | Fisher Asset Management, LLC | 118.7K | $33.1M | -12.4K (-9.5%) | Trimmed |
| 18 | VANGUARD FIDUCIARY TRUST CO | 113.6K | $31.7M | — | New |
| 19 | Allianz Asset Management GmbH | 110.2K | $30.7M | +37 (+0.0%) | Added |
| 20 | FEDERATED HERMES, INC. | 109.9K | $30.6M | -4.0K (-3.5%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BIO's latest filing finishes processing.